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Cervical dystonia (CD) is the most frequent form of focal dystonia. Symptoms often result 
in pain and functional disability. Local injections of botulinum neurotoxin are currently the 
treatment of choice for CD. Although this treatment has proven effective and is widely 
applied worldwide, many issues still remain open in the clinical practice. We performed 
a systematic review of the literature on botulinum toxin treatment for CD based on a 
question-oriented approach, with the aim to provide practical recommendations for 
the treating clinicians. Key questions from the clinical practice were explored. Results 
suggest that while the beneficial effect of botulinum toxin treatment on different aspects 
of CD is well established, robust evidence is still missing concerning some practical 
aspects, such as dose equivalence between different formulations, optimal treatment 
intervals, treatment approaches, and the use of supportive techniques including elec-
tromyography or ultrasounds. Established strategies to prevent or manage common 
Abbreviations: ADL, activities of daily living; BoNT, botulinum neurotoxin; CD, cervical dystonia; CMAP, compound muscle 
action potential; DBS, deep brain stimulation; EMG, electromyography; IU, international units; NAB, neutralizing antibod-
ies; QoL, quality of life; RCTs, randomized controlled trials; SNR, secondary non-responsiveness; SPC, summary of product 
characteristics; TWSTRS, Toronto Western Spasmodic Torticollis Rating Scale.
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iNTRODUCTiON
Cervical dystonia (CD) is the most frequent form of focal dys-
tonia, with an overall prevalence of 4.98/100,000 in Europe (1). 
CD is characterized by abnormal postures of head and neck that 
can considerably impair activities of daily living (ADL), with pain 
occurring in 43.1% of patients (2). Mood disorders, including 
anxiety and depression, are frequently present (3, 4).
Oral medication has a limited role. Trihexyphenidyl is 
classically proposed, but the tolerance profile is low (5). 
Benzodiazepines, especially diazepam and clonazepam, mainly 
reduce dystonia-related pain, anxiety, and possibly dystonic 
tremor (6). Tetrabenazine, although possibly effective (7), is lim-
ited by the frequent side effect of depression and parkinsonism. 
Evidence on the effectiveness of allied care treatments, including 
physiotherapy and cognitive behavioral therapy, is scanty (8). 
In those with unsatisfactory botulinum neurotoxin (BoNT) 
effect, surgery may be considered. Peripheral surgery, such as 
selective peripheral denervation, can provide improvement in 
about two-thirds of cases, with frequent relapses and is now 
rarely performed (9, 10). Deep brain stimulation (DBS) of the 
globus pallidus pars interna appears to be a better choice, despite 
potential severe complications (11). Alternative DBS targets, such 
as the subthalamic nucleus, need further investigation (12).
Local injections of BoNT are currently the treatment of 
choice for CD. By binding to peripheral cholinergic nerve end-
ings in the neuromuscular junction, BoNT decreases the release 
of acetylcholine at the motor neuron in the synaptic cleft, thus 
blocking neuromuscular transmission and provoking muscle 
weakness (13).
Botulinum neurotoxin type A is the most frequently used; type 
B is only proposed in selected cases.
Although BoNT treatment is widely applied worldwide, many 
questions remain open in clinical practice.
Some aspects of this treatment have been largely explored 
in the literature, and robust evidence is available. Other aspects 
still deserve attention and univocal answers and directives are 
lacking.
In this paper, literature on BoNT treatment for CD was 
systematically reviewed based on a question-oriented practical 
approach. The aim was to provide practical recommendations on 
common issues in clinical practice.
To this end, we reviewed the evidence concerning the com-
parison of different formulations of BoNT in improving motor 
symptoms, pain, and quality of life (QoL), also in relation to the 
dosage conversion ratio, which is a long debated topic.
Another common issue in the daily practice, which demands 
stronger evidence is how to prevent and manage side effects and 
complications, including the formation of neutralizing antibodies 
(NAB) and treatment side effects such as dysphagia, neck muscle 
paresis, or pain at injection site.
Due to the nature of the treatment itself, which involves 
intramuscular injections and a neurochemical denervation, 
questions may arise concerning potential contraindications 
such as the use of anticoagulants or the presence of concomi-
tant neuromuscular disorders, in addition to pregnancy and 
lactation.
We finally explored issues related to the optimization of 
the treatment, including the optimal initial dose of BoNT, and 
whether injection strategy can be improved by applying multiple 
injection points instead of single injection points or by using 
neurophysiological techniques or associated physiotherapy. 
These topics have been touched upon in some studies, but the use 
of different methodologies, protocols, and sometimes patients’ 
populations makes it difficult to directly compare the results.
MeTHODS
The aim of this manuscript was to provide a literature review 
focused on some specific question arising from the clinical 
practice.
A structured literature review was conducted, by using appro-
priate keywords covering the topic of BoNT treatment for CD. A 
language restriction to English, French, German, and Dutch was 
applied. All kind of studies were reviewed and studies carried out 
before 1980 were excluded.
information Sources
Three databases were searched: Medline and Embase using the 
Ovid interface, and the Cochrane library.
Selection of Papers
In all three databases, we identified systematic reviews, rand-
omized controlled trials (RCTs), health economic evaluation 
studies, and, in both Medline and Embase, also observational 
studies. The complete search strategy is reported in File S1 in 
Supplementary Material.
Review Method
All the papers were screened for topic appropriateness on 
abstract basis by two independent reviewers with successive 
agreement on discrepancies. Papers were then assigned to dif-
ferent coauthors according to predefined key clinical questions.
To assess the quality of the published studies, the classification 
scheme for level of evidence and the level of recommendation of 
the American Academy of Neurology was used (14) (File S2 in 
Supplementary Material). The recommendation level is reported 
for each statement.
side effects (including excessive muscle weakness, pain at injection site, dysphagia) and 
potential contraindications to this treatment (pregnancy and lactation, use of anticoagu-
lants, neurological comorbidities) should also be further explored.
Keywords: botulinum toxin, cervical dystonia, recommendations, efficacy, side effects, treatment strategy
TaBle 1 | effect of different formulations of BoNT on CD.
Question answer level of 
recommendation
Is abobotulinumtoxinA effective in 
improving CD?
Yes A
Is incobotulinumtoxinA effective in 
improving CD?
Yes B
Is onabotulinumtoxinA effective in 
improving CD?
Yes A
Is rimabotulinumtoxinA effective in 
improving CD?
Yes A
Does BoNT-A treatment improve 
quality of life?
Yes B
Does BoNT-A reduce pain associated 
with CD?
Yes A
Do BoNT-A and BoNT-B have a 
comparable effect and duration of 
effect on dystonia?
Yes A
Do BoNT-A and BoNT-B have the 
same rate of side effects?
No (side effects 
are more frequent 
with BoNT-B)
B
What is the conversion ratio 
of onabotulinumtoxinA to 
abobotulinumtoxinA?
1 IU to 3 IU
1 IU to 2.5 IU
A
B
What is the conversion ratio 
of onabotulinumtoxinA to 
incobotulinumtoxinA?
1 IU to 1 IU B
BoNT, botulinum neurotoxin; CD, cervical dystonia.
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ReSUlTS
effect of Different BoNT Formulations on 
CD (Table 1)
Three BoNT-A products are commercially available: onabotuli-
numtoxinA (Botox®, Allergan), abobotulinumtoxinA (Dysport®, 
Ipsen), and incobotulinumtoxinA (Xeomin®, Merz). These prod-
ucts differ concerning the added preservatives, the toxin solubility, 
and the relative potencies. Only one type of BoNT-B is available: 
rimabotulinumtoxinB (Neurobloc®/Myobloc®, Elan Pharma).
Are the Different Formulations of BoNT-A and 
BoNT-B Effective in Improving CD?
Several RCTs showed that onabotulinumtoxinA, abobotuli-
numtoxinA, and rimabotulinumtoxinB are effective in reducing 
dystonia when compared to placebo (15–25).
One RCT showed that incobotulinumtoxinA (at both doses 
of 120 IU and 240 IU) significantly improved Toronto Western 
Spasmodic Torticollis Rating Scale (TWSTRS)-total scores com-
pared to placebo in 233 CD patients (26) and that improvement 
of mean TWSTRS-total (p < 0.001) and severity score (p < 0.016) 
persisted after repeated injection (up to 5) (27).
Conclusion and Recommendations
There is class I evidence that the three BoNT-A and the 
BoNT-B formulations significantly improve dystonia in CD. 
The recommendation level is A for abobotulinumtoxinA, 
onabotulinumtoxinA, and rimabotulinumtoxinB, and level B for 
incobotulinumtoxinA (26).
Does BoNT-A Treatment Improve QoL?
In a double-blind RCT, treatment with 500 IU of abobotulinum-
toxinA produced significantly greater improvements than pla-
cebo in Physical Functioning, Role Physical, Bodily Pain, General 
Health, and Role Emotional domains of the SF-36 (p ≤ 0.03) (28).
Conclusion and Recommendations
There is class I evidence that BoNT-A improves QoL in CD 
(level B).
Does BoNT-A Reduce Pain Associated with CD?
In five RCTs with a total of 162 CD patients, 71% of the patients 
treated with onabotulinumtoxinA and abobotulinumtoxinA 
reported pain reduction compared with 12% of the patients in the 
placebo group (p < 0.00001) (29). Pain was also improved with 
incobotulinumtoxinA in both single-set injections and long-term 
treatment (26, 27).
Conclusion and Recommendations
There is class I evidence that BoNT-A reduces pain symptoms in 
CD (level A).
Do BoNT-A and BoNT-B Have Comparable Effects?
In two RCTs (30, 31), no difference was found in the size and 
duration of effect on the total TWSTRS score and sub-scores 
(dystonia severity, limitations, and pain score) between BoNT-A 
and BoNT-B. Dry mouth and swallowing difficulties were more 
common with BoNT-B (30, 32).
Conclusion and Recommendations
Botulinum neurotoxin-A and BoNT-B have a comparable effect 
and duration of effect (level A).
Side effects are more frequent with BoNT-B (class I evidence, 
level B).
What Is the Conversion Ratio of Different 
Formulations of BoNT-A?
The conversion factor between the different formulations is still 
a matter of discussion.
OnabotulinumtoxinA vs. AbobotulinumtoxinA
LD50 tests have shown 1:1 potency ratio of incobotulinumtoxinA 
vs. onabotulinumtoxinA (33), and 2.3:1 of abobotulinumtoxinA 
vs. onabotulinumtoxinA. These data however cannot be directly 
translated into the clinical practice (34).
In a retrospective study, changing from onabotulinumtoxinA 
to abobotulinumtoxinA with a conversion rate of 1:2 resulted in a 
tendency toward higher efficacy but more adverse events (35). At 
6.5 years follow-up, the doses had been reduced, and the median 
dose conversion ratio had decreased to 1:1.7.
In a double-blind study, 79 healthy controls were randomized 
into 18 groups, receiving different doses and concentrations of 
onabotulinumtoxinA or abobotulinumtoxinA (36). Both toxins 
caused a comparable, significant decline in the compound 
muscle action potential (CMAP). A statistical model with 
TaBle 2 | Optimization of BoNT treatment for CD.
What is the recommended initial dose for 
treatment of CD with abobotulinumtoxinA?
500 IU (although other 
dosages might be used)
A
What is the recommended initial dose for 
treatment of CD with incobotulinumtoxinA?
120 IU B
What is the recommended initial dose for 
treatment of CD with onabotulinumtoxinA?
No recommendation U
What is the recommended initial dose for 
treatment of CD with rimabotulinumtoxinB?
2,500 or 5,000 IU
10,000 IU
B
A
Can prior polymyographic EMG (pEMG) 
and EMG guidance improve the treatment 
outcome in treatment-naïve patients?
Yes A
Can prior pEMG and EMG guidance 
improve the treatment outcome in patients 
with deterioration of treatment effect?
Yes C
Are multiple-points injections per muscle 
more effective than single-point injections?
Yes U
Can additional physiotherapy improve the 
effect of BoNT treatment?
No (motor improvement 
as measured by 
TWSTRS or Tsui score)
C
Yes (disability and pain 
and prolongs the effect 
of BoNT)
U
BoNT, botulinum neurotoxin; CD, cervical dystonia; EMG, electromyography; TWSTRS, 
Toronto Western Spasmodic Torticollis Rating Scale.
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CMAP data indicated a bioequivalence of 1 IU onabotulinum-
toxinA:1.57  IU abobotulinumtoxinA and a maximum dose-
equivalence ratio of 1:3.
In a comparative clinical study, 73 CD patients were 
randomized for onabotulinumtoxinA or abobotulinumtoxinA 
with a dose ratio of 1:3  IU (37). The improvement of Tsui 
score, the duration of effect, and the rate of side effects were 
comparable.
Two different conversion factors (1:3 and 1:4) between 
onabotulinumtoxinA and abobotulinumtoxinA were tested in 
a double-blind randomized three-period crossover study in 54 
CD patients (38). AbobotulinumtoxinA was significantly more 
effective than onabotulinumtoxinA in reducing Tsui score, with 
no significant difference between the two conversion ratios. The 
adverse events were more frequent in the abobotulinumtoxinA 
group, but only significantly for the 1:4 conversion.
A recent double-blind, randomized, crossover study using 
a conversion ratio of 1:2.5  IU showed comparable efficacy and 
adverse effects (39).
Conclusion and Recommendations
It is recommended to use a conversion of 1 IU onabotulinum-
toxinA to 3 IU abobotulinumtoxinA (level A) (37, 38), although 
conversion ratios of 1:2.5 might be equally safe and effective 
(class I, level B) (39).
OnabotulinumtoxinA vs. IncobotulinumtoxinA
In an open label prospective crossover study, 40 patients initially 
treated with onabotulinumtoxinA were randomly assigned to 
treatment switch to incobotulinumtoxinA with a 1:1 ratio (33). 
Inter-injection intervals and treatment duration showed compa-
rable efficacy for at least four injection cycles. Comparable effi-
cacy on TWSTRS and adverse-event profiles for up to 16 weeks 
were also reported in a randomized, double-blind, parallel-group, 
non-inferiority trial, with CD patients randomized to incobotu-
linumtoxinA or onabotulinumtoxinA with the same conversion 
factor of 1:1 (40).
Conclusion and Recommendations
It is recommended to use a conversion of 1:1 IU onabotulinum-
toxinA to incobotulinumtoxinA (class I, level B).
Optimization of BoNT Treatment for  
CD (Table 2)
What Is the Recommended Initial BoNT Dose for 
Treatment of CD?
According to the respective summary of product characteristics 
(SPC—last accessed 08/04/2015), the suggested starting total 
dose is 500  IU in two-three muscles, for abobotulinumtoxinA 
(SPC last text revision 11/12/2013), and <200 IU (50 IU/injection 
and maximum 100 IU to the sternocleidomastoid) for onabotuli-
numtoxinA (SPC, 19/03/2015). For incobotulinumtoxinA, a total 
dose of 200 IU is mentioned, with doses up to 300 IU allowed 
(50 IU/injection—SPC, 16/11/2012). For rimabotulinumtoxinB, 
an initial dose of 5,000  IU may be considered, but a dose of 
10,000 IU divided between two and four muscles may be more 
effective (SPC, 26/02/2014).
In an RCT, 73 patients were randomized into four groups 
treated with placebo, abobotulinumtoxinA 250, 500, or 1,000 IU, 
divided between one splenius capitis and the contralateral sterno-
cleidomastoid muscle (21). The greatest improvement was found 
in the group treated with 1,000 IU, although significantly more 
side effects were reported. An initial dose of 500 IU abobotuli-
numtoxinA (divided into 100–200 IU in the sternocleidomastoid 
muscle, 250–350 IU in the splenius, 100–200 IU in the trapezius, 
and 100–200 IU in the levator scapulae) significantly improved CD 
with respect to placebo in another RCT on 68 patients (41). Based 
on these results, an initial dose of 500 IU abobotulinumtoxinA 
is suggested. It is worth mentioning, however, that CD could be 
successfully treated using an average total dose of 200–400  IU 
abobotulinumtoxinA under electromyography (EMG) guidance, 
resulting also in fewer side effects (42).
A starting dose of 50–100  IU of onabotulinumtoxinA per 
muscle, with a maximum dose per session of 280 IU, was used in a 
study on 32 patients. A documented improvement in both subjec-
tive and objective parameters was observed in 75% of patients 
(43). The mean total doses of original onabotulinumtoxinA injec-
tions, reported in 30 studies, as assessed by a systematic review, 
ranged from 60 to 374 IU in total (44).
In an RCT, both doses of 120  IU and 240  IU incobotu-
linumtoxinA significantly improved the TWSTRS-total scores 
compared to placebo in previously treated and treatment-naive 
subjects, with mild side effects. Initial dose 120 IU of incobotu-
linumtoxinA has been suggested based on these results (26).
Three double-blind, randomized, placebo-controlled studies 
(20, 22, 23) have shown that the effect of botulinum toxin B 
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injections in doses of 2,500, 5,000, and 10,000 IU was significantly 
higher compared to placebo, with the highest clinical effect seen 
with dose of 10,000 IU as measured by the TWSTRS-total score. 
The incidence of mild dysphagia was higher in the 10,000  IU 
group (16, 10, and 27%, respectively, as compared to no patient 
who received placebo) (20).
Conclusion and Recommendations
An initial total dose of 500 IU abobotulinumtoxinA is effective 
(level A), although other dosages might be used (41, 45).
An initial total dose of 120 IU incobotulinumtoxinA is prob-
ably effective (evidence class I, level B) (26).
No clear recommendations can be given on the optimal start-
ing does of onabotulinumtoxinA (level U).
An initial total dose of 2,500 or 5,000 IU rimabotulinumtox-
inB (evidence class I, level B) or 10,000 IU (level A) is probably 
effective.
Can Prior Polymyographic EMG (pEMG) and 
Simultaneous EMG Improve the Treatment 
Outcome?
In one RCT, 52 CD patients were randomized into a pEMG-
group (treated muscles selected based on clinical evaluation and 
pEMG, and BoNT injected using simultaneous EMG) or control 
group (muscles selected based solely on clinical examination and 
injected without EMG) (46). Improvement on the TWSTRS was 
higher in the pEMG with EMG assistance group (14 vs. 5%).
In a randomized prospective, blinded study on 26 treatment-
naive patients, the objectively measured clinical outcome was 
significantly better when the muscle selection was based on 
quantitative EMG and treatment was performed with simultane-
ous EMG, than when treatment was based on clinical judgment 
alone (47).
Other studies showed that without pEMG, 24–41% of the dys-
tonic muscles were missed, and 25–35% of the injected muscles 
were misjudged as dystonic (47–49).
A retrospective study explored results of treatment with pEMG 
in 40 patients with previously unsatisfactory treatment response 
(50). After 1 year, a significant improvement in both Tsui scores 
and subjective evaluation was observed. pEMG led to change in 
injection pattern in 96% of the patients.
In another study, 8/10 CD patients with deterioration of treat-
ment effect, achieved marked improvement (64% on TWSTRS) 
after pEMG guided injections (51).
The identification of motor endplate zones with high-density 
surface EMG may help decreasing the BoNT dose by keeping the 
effect unaltered (52).
Conclusion and Recommendations
There is class I evidence that, in treatment-naïve patients, 
improvements in dystonia and pain are greater if muscles are 
selected based on a combination of clinical examination and 
pEMG and injections are performed with EMG guidance (level 
A) (46, 47).
In patients with deterioration of treatment effect, the use of 
pEMG and EMG guidance can improve the results (class III, 
level C) (50, 51).
Are Multiple-Points Injections per Muscle More 
Effective than Single-Point Injections?
No RCTs on this topic were found. A comparative study in 
49  patients showed that multiple injections are more effective 
than a single injection in improving dystonia, pain, posture 
deformity, range of motion, and activity endurance (53). Experts 
recommend the administration of one to four injections per 
muscle, depending on the volume of the muscle (4, 54).
Conclusion and Recommendations
There are indications (class III) that multi-point BoNT injec-
tions are more effective than single-point BoNT injections 
(level U).
Can Physiotherapy Improve the Effect of BoNT 
Treatment?
In one single-blind RCT, no significant difference was found 
between patients randomized to BoNT treatment combined 
with relaxation therapy alone or with a 12-week physiotherapy 
program and relaxation therapy (55).
In one crossover RCT on 40 patients, significantly greater 
reductions in disability in ADL and subjective pain were 
observed after a 6-week additional physiotherapy, with respect 
to BoNT treatment alone. In addition, clinical benefit lasted 
longer and a lower BoNT dose was needed at reinjection. No 
significant differences were observed on the Tsui scale and 
TWSTRS (56).
In a case–control open study, 40 patients followed a 4-week 
physiotherapy program combined with BoNT treatment or BoNT 
treatment alone. The physiotherapy group showed significantly 
more improvement on the pain subscale of the TWSTRS, and on 
some subscales of the SF-36 (57).
Conclusion and Recommendation
Adding physiotherapy in combination with BoNT treatment 
does not produce a greater motor improvement as measured by 
TWSTRS or Tsui (class II, level C) (55).
Adding physiotherapy to BoNT treatment may improve dis-
ability, pain, and prolong the effect of BoNT [class III (4) and IV 
(57), level U].
Primary and Secondary  
Non-Responsiveness (SNR) (Table 3)
Primary non-responsiveness to BoNT, defined as lack of treat-
ment effect from the first application, and due to genetically 
induced resistance (58) or a prior (unnoticed) botulism (59), is 
exceptional. Technical aspects such as insufficient dosing, errors 
during drug storage and reconstitution, or improper injection 
sites could also lead to an initial lack of response, usually amended 
in successive treatments.
Secondary non-responsiveness is defined as “insufficiently 
improved posture after three or more unsuccessful injection 
cycles in CD patient’s previously achieving satisfactory results” 
(60). SNR concerns around 3–5% of the patients (61).
The formation of NAB, with estimated frequency in CD 
patients varying from 1.2% (62) to 40% (63), is one of the 
causes of SNR. NAB have been found in patients treated with 
TaBle 3 | Primary and SNR.
Are treatment intervals 
<12 weeks safe?
Yes (incobotulinumtoxinA)
No recommendation (rimabotulinumtoxinB, 
onabotulinumtoxinA, and abobotulinumtoxinA)
U
U
Which treatment 
strategies are useful in 
case of non-response to 
BoNT-A treatment?
Keeping the treatment intervals constant 
(early detection of SNR)
U
Repeated plasma exchange (contrasting 
NAB-induced SNR)
U
Switching to BoNT-B produces only 
temporary benefit
U
BoNT, botulinum neurotoxin; NAB, neutralizing antibodies; SNR, secondary non-
responsiveness.
6
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onabotulinumtoxinA, abobotulinumtoxinA, and rimabotuli-
numtoxinB (64). RimabotulinumtoxinB seems more likely to 
elicit SNR than BoNT-A: antibody-induced therapy failure was 
shown in 44% of CD patients treated with BoNT-B during a 
short period (65). The development and titer of NAB does not 
correlate with the entity of SNR, and there is evidence that the 
mere detection of NAB does not necessarily indicate the pres-
ence of SNR (66, 67). No antibodies are described after treat-
ment with incobotulinumtoxinA in naive CD patients (68, 69), 
while this has been reported in one patient previously treated 
with another BoNT (33).
Factors significantly associated with SNR include previous 
recourse to other therapies such as surgical interventions, 
physical therapy and neuroleptic use, a higher number of seri-
ous adverse events, more frequent treatment interruptions, and 
higher average BoNT-A doses during the last three injection 
cycles (67).
Are Treatment Intervals <12 Weeks Safe?
No controlled studies have compared the long-term immuno-
genicity of different BoNT-A.
In a consensus statement, experts recommend that reinjection 
is left as long as clinically possible, to minimize the chance of 
antibody responses (4).
The current manufacturer information suggest that the 
minimal interval between injections should be 10 (SPC onabotu-
linumtoxinA and incobotulinumtoxinA) to 12 weeks (SPC abo-
botulinumtoxinA). This information, however, was based on data 
obtained with the original formulation of onabotulinumtoxinA, 
which contained a higher protein load (70, 71).
Fixed 3-month intervals may result in a decrease in treat-
ment satisfaction toward the end of the period. Indeed up to 
45% of patients indicated a preference for treatment intervals 
≤10 weeks (72).
In a trial with incobotulinumtoxinA, where injection sessions 
were administered at intervals of 6–20 weeks, there were no dif-
ferences in the tolerability profile in the group of patients injected 
at 6–14 weeks with respect to the other groups (27).
Conclusion and Recommendations
There is only one class I study showing that, with incobotulinum-
toxinA, treatment intervals <12 weeks do not increase the risk of 
developing antibodies. There is insufficient data to recommend 
or discourage the use of an interval <12 weeks for treatment with 
rimabotulinumtoxinB, onabotulinumtoxinA, and abobotuli-
numtoxinA (level U).
Which Treatment Strategies Are Useful in Case of 
SNR to BoNT-A Treatment?
Secondary non-responsiveness develops gradually, starting with 
a reduced duration of clinical effect and culminating with sig-
nificant reduction of the maximal effect (73). Therefore, constant 
treatment intervals and careful scoring of treatment effect may 
lead to an early detection of SNR (74). However, whether an 
early detection is useful to prevent the development of SNR and 
the induction of high titers of NAB is unclear, considering the 
absence of effective prevention strategies.
Switching from BoNT-A to BoNT-B in patients with SNR due 
to NAB may initially result in effective treatment; however, most 
of these patients will eventually develop antibodies to BoNT-B as 
well (75, 76).
Neutralizing antibodies depletion by repeated plasma 
exchange in one patient with SNR, allowed recovery of BoNT-A 
treatment effect (77).
Conclusion and Recommendations
It is suggested that keeping the treatment intervals constant may 
lead to early detection of SNR (level U).
Repeated plasma exchange is possibly effective in contrasting 
NAB-induced SNR (level U).
Switching to treatment with BoNT-B produces only temporary 
recovery of effect, often followed by development of antibodies 
against BoNT-B (level U).
Management of Side effects of BoNT 
Treatment (Table 4)
What Is the Most Effective Strategy to Avoid 
Dysphagia following BoNT Treatment?
Swallowing difficulty is caused by BoNT spreading to the throat 
muscles. Bilateral sternocleidomastoid injections are more fre-
quently associated with dysphagia (54). Dysphagia is often mild 
(severe in <5% of the cases), very rarely requires hospitalization 
or feeding tube, and disappears gradually after 2–3 weeks (54). 
Dysphagia is relatively common: 7.1% of the patients reported 
dysphagia after treatment with the original onabotulinumtoxinA, 
3.4% with the new generation onabotulinumtoxinA, 19.4% with 
abobotulinumtoxinA, 12.6% with incobotulinumtoxinA, and 
15.6% with rimabotulinumtoxinB (26, 44, 78). Different tendency 
to spread into surrounding muscles could rely on differences in 
formulation, size of the protein molecules, or dilution factor, 
although these results are based on heterogeneous studies in 
terms of patient selection, dose, and injected muscles (44).
In a study, five CD patients who had reported 34 episodes of 
dysphagia over 98 EMG-guided injections (34.7%) were treated 
with additional use of ultrasounds: this resulted in no episodes of 
dysphagia across 27 injection sessions (79).
Conclusion and Recommendations
The additional use of ultrasound may lessen recurrent dysphagia 
after botulinum treatment (class IV, level U).
TaBle 4 | Side effects and contraindications of BoNT treatment for CD.
What is the most effective 
to avoid dysphagia?
The additional use of ultrasound may 
lessen recurrent dysphagia
U
What is the most effective 
strategy in case of neck 
muscles paresis?
The use of a soft collar can relieve the 
symptoms of neck extensor muscles 
paresis
U
What is the most effective 
strategy to prevent 
injection pain?
Skin cooling or local application of 
anesthetic cream reduce injection pain
U
Is BoNT treatment safe 
during pregnancy and 
lactation?
BoNT treatment during pregnancy and 
lactation is not recommended and should 
be avoided whenever possible
U
Is BoNT treatment safe 
for CD patients who use 
anticoagulants?
The risk of hematoma following BoNT 
treatment by concomitant use of coumarin 
derivatives is low
U
Is BoNT treatment safe 
for CD patients with 
concomitant neurological 
comorbidities?
Patients with concomitant impairment 
of neuromuscular transmission may 
experience clinical deterioration after BoNT 
treatment, although in selected cases 
treatment might be safe and beneficial
U
BoNT, botulinum neurotoxin; CD, cervical dystonia.
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What Is the Most Effective Strategy in Case of Neck 
Muscles Paresis following BoNT Treatment?
Weakness of the neck extensors is a common side effect of BoNT 
treatment in these muscles. The symptoms are usually mild and 
are generally resolved within a few weeks (54). According to a 
systematic review, this side effect was reported by 62/339 (18%) 
of the patients treated with onabotulinumtoxinA or abobotu-
linumtoxinA, compared with 9/266 (3%) of the patients in the 
placebo group (80). In an RCT on 233 patients, neck weakness 
was reported in 6–10% of patients treated with incobotuli-
numtoxinA 120 or 240 IU, respectively, as compared to 1% of 
patients treated with placebo (26).
There is no evidence to support the use of a soft collar, although 
this measure can relieve symptoms of paresis (4).
Conclusion and Recommendations
The use of a soft collar can relieve the symptoms of neck extensor 
muscles paresis (class IV, level U).
What Is the Most Effective Strategy to Prevent Pain 
at the Injection Site?
In RCTs comparing BoNT-A treatment to placebo, injection pain 
occurs equally in both groups (4). This pain is usually present for 
only a few days and is rarely a reason to terminate the BoNT-A 
treatment (54).
Skin cooling (with ethylchloride spray, dry cold, or ice) or local 
application of anesthetic cream decreases pain associated with 
limb or facial botulinum injections (81–83). As such, they may 
be beneficial in patients for the treatment of CD too, although no 
specific studies were found.
Conclusion and Recommendations
Skin cooling or local application of anesthetic cream can reduce 
injection pain (class IV, level U).
Contraindications for  
BoNT Treatment (Table 4)
Is BoNT Treatment Safe during Pregnancy and 
Lactation?
OnabotulinumtoxinA is classified as pregnancy Category C by 
FDA: “Animal reproduction studies have shown an adverse effect 
on the fetus and there are no adequate and well-controlled studies 
in humans, but potential benefits may warrant use of the drug in 
pregnant women despite potential risks. This drug should be used 
during pregnancy only if the benefit outweighs the risk to the fetus.” 
Animal studies have provided no indications of harm during preg-
nancy with doses of BoNT-A normally used in clinical practice (84).
Results of a survey on 396 doctors showed that a total of 
16 pregnant women had been treated with BoNT, primarily in 
the first trimester. One patient (8.3%) had a miscarriage, while 
the other patients gave birth to healthy children after full-term 
pregnancies (85).The overall risk of miscarriage, regardless of 
the cause, is 15–20% (86). In the literature, up to 25 women are 
described who have been treated during each stage of pregnancy: 
two miscarriages were reported in women with previous history 
of miscarriage; the other cases reported uneventful pregnancy 
and healthy children (87).
No studies were found on the use of BoNT during lactation. 
Due to insufficient data, the manufacturers do not recommend 
using BoNT during lactation, although it seems unlikely that 
BoNT may enter breast milk (84).
Conclusion and Recommendations
Although several cases have been reported of safe use of BoNT 
during pregnancy, the effect of BoNT on the unborn child has 
been insufficiently studied in humans; therefore, BoNT treatment 
during pregnancy is not recommended and should be avoided 
whenever possible (class IV, level U).
No studies have been conducted on the effect of BoNT on the 
nursing child; to exclude side effects, BoNT treatment should be 
avoided during lactation (class IV, level U).
Is BoNT Treatment Safe for CD Patients Who Use 
Anticoagulants?
No reports of complications resulting from the use of coumarin 
derivatives or non-vitamin K antagonist oral anticoagulants by 
CD patients treated with BoNT were found. According to the SPC 
of coumarin derivates, intramuscular injections are discouraged 
(but not explicitly forbidden) because of the increased risk of 
hematomas, while no limitation is reported for subcutaneous 
injections. The incidence of hematoma after BoNT injection was 
marginally increased in a group of 32 patients treated with phen-
procoumon (3%) with respect to 32 control patients (1.8%) (88).
Conclusion and Recommendations
The risk of hematoma following BoNT treatment by concomitant 
use of coumarin derivatives has not been sufficiently studied but 
seems low (class IV, level U).
Is BoNT Treatment Safe for CD Patients with 
Concomitant Neurological Comorbidities?
Treatment with BoNT may exacerbate symptoms of coexist-
ent neuromuscular diseases (89, 90) or unmask subclinical 
cases (91, 92). Myasthenia gravis, amyotrophic lateral sclerosis, 
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and Lambert–Eaton diseases are reported as contraindications to 
BoNTs treatment in the respective SPCs, although cases of safe 
CD treatment in patients with myasthenia or amyotrophic lateral 
sclerosis have occasionally been reported (93, 94).
Generalized weakness has been rarely reported after BoNT 
injections, most frequently in patients treated for spasticity 
(95, 96).
Conclusion and Recommendations
Patients with preexistent impairment of neuromuscular transmis-
sion may experience clinical deterioration after BoNT treatment, 
although in selected cases treatment might be safe and beneficial 
(class IV, level U).
GeNeRal CONSiDeRaTiONS
Overall, there is a solid bulk of evidence supporting a good benefi-
cial effect of the different formulations of BoNT in the treatment 
of CD, with a good benefit-to-risk ratio and a sustained effect 
over time. However, there is still room for strategies to further 
improve the efficacy and safety of this treatment. Robust evidence 
is missing concerning some practical aspects, such as treatment 
approaches, and the use of supportive techniques including EMG 
or ultrasounds. Existing knowledge often comes from secondary 
outcome measures in larger studies designed for other research 
questions. These studies often use variable methods and outcome 
measures, which makes comparisons difficult. Future studies 
should focus on these topics, by using standardized approaches 
and focusing on only one research question.
It has been noticed that the reported results are not always 
applicable to the daily practice. This may partly be due to the 
fact that, in the case of BoNT, optimal treatment requires some 
variability, according to the needs of the patients and to the 
progression of the symptoms. The design of future studies should 
also take this aspect into account.
Although the incidence of adverse events related to BoNT injec-
tions, including the formation of NAB, is low, there is a need for 
established strategies to prevent or manage common side effects 
of this treatment. To this end, multicentre collaborations are war-
ranted in order to be able to collect an informative number of cases.
Some of the main clinical questions, including the dose 
equivalence between different formulations and the minimum 
safe treatment intervals, are matter of discussion already for 
several years. This knowledge gap could only be addressed by 
research groups willing to engage in well designed and adequately 
powered clinical studies.
The continuous commitment of clinicians and basic scientist 
to produce robust evidence concerning these and other open 
questions arising from the clinical practice, is fundamental to 
improve QoL of CD patients.
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